- Home
- GALT vs QTRX Comparison
GALT vs QTRX Comparison
Compare GALT & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- QTRX
- Stock Information
- Founded
- GALT 2000
- QTRX 2007
- Country
- GALT United States
- QTRX United States
- Employees
- GALT N/A
- QTRX N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- QTRX Biotechnology: Laboratory Analytical Instruments
- Sector
- GALT Health Care
- QTRX Industrials
- Exchange
- GALT Nasdaq
- QTRX Nasdaq
- Market Cap
- GALT 232.3M
- QTRX 241.2M
- IPO Year
- GALT N/A
- QTRX 2017
- Fundamental
- Price
- GALT $5.67
- QTRX $5.21
- Analyst Decision
- GALT Strong Buy
- QTRX Hold
- Analyst Count
- GALT 3
- QTRX 4
- Target Price
- GALT $6.00
- QTRX $11.75
- AVG Volume (30 Days)
- GALT 339.7K
- QTRX 522.3K
- Earning Date
- GALT 11-14-2025
- QTRX 11-10-2025
- Dividend Yield
- GALT N/A
- QTRX N/A
- EPS Growth
- GALT N/A
- QTRX N/A
- EPS
- GALT N/A
- QTRX N/A
- Revenue
- GALT N/A
- QTRX $125,784,000.00
- Revenue This Year
- GALT N/A
- QTRX N/A
- Revenue Next Year
- GALT N/A
- QTRX $37.03
- P/E Ratio
- GALT N/A
- QTRX N/A
- Revenue Growth
- GALT N/A
- QTRX N/A
- 52 Week Low
- GALT $0.73
- QTRX $4.05
- 52 Week High
- GALT $6.55
- QTRX $15.67
- Technical
- Relative Strength Index (RSI)
- GALT 62.88
- QTRX 42.84
- Support Level
- GALT $5.04
- QTRX $4.93
- Resistance Level
- GALT $5.36
- QTRX $5.46
- Average True Range (ATR)
- GALT 0.33
- QTRX 0.30
- MACD
- GALT 0.05
- QTRX -0.10
- Stochastic Oscillator
- GALT 60.81
- QTRX 21.51
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.